Example A — MRI-fusion biopsy, targeted + systematic, two lesions
Clinical: Elevated PSA; MRI shows two PI-RADS 4 lesions; transperineal fusion biopsy with systematic cores plus targeted cores of both lesions.
Code(s): 55710 – transperineal fusion, targeted + systematic (first lesion); 55715 x 1 – second targeted lesion (expect the MUE auto-denial; appeal with records).
Dx: R97.20 elevated PSA (or documented indication).

Example B — Ultrasound-guided transrectal biopsy
Clinical: Elevated PSA; standard systematic transrectal ultrasound-guided biopsy in the office.
Code(s): 55707. (55715 is not reportable with straight ultrasound codes.)
Dx: R97.20 elevated PSA.

Example C — Active surveillance follow-up
Clinical: Established patient with Gleason 6 disease on active surveillance; PSA reviewed and stable; plan to continue surveillance with repeat PSA in 6 months.
Code(s): Established-patient E/M leveled on documented problem complexity, data reviewed, and management risk.
Dx: C61 (cancer present, actively managed by surveillance).

Example D — ADT injection visit
Clinical: Patient on leuprolide for advanced disease receives his scheduled depot injection by clinical staff.
Code(s): 96402 + J9217 (units per dose). Bill an E/M with modifier -25 only when a significant, separately identifiable service was performed and documented.
Dx: C61; add Z19.1 or Z19.2 for hormone sensitivity status when documented.

Example E — Robotic radical prostatectomy with lymphadenectomy
Clinical: Localized intermediate-risk disease treated with robot-assisted laparoscopic radical prostatectomy and bilateral pelvic lymph node dissection.
Code(s): 55866; 38571 when a separately documented bilateral pelvic lymphadenectomy is performed [VERIFY: NCCI pairing for 55866 + 38571].
Dx: C61.

• Approach: transrectal or transperineal
• Guidance: ultrasound only, MRI-fusion, or in-bore CT/MRI
• Targeting: systematic cores, targeted cores, or both; each targeted lesion tied to the region of interest on the previously interpreted MRI
• Lesion count: the number of distinct lesions targeted — this drives 55715 units and the appeal record
• Core labeling: specimen labeling that matches the targeting described

• Problem status: cancer status (active vs history of), risk category, treatment phase
• Data reviewed: PSA trend, imaging, pathology actually referenced in the decision
• Management risk: surveillance decision, drug management discussion (risks/benefits, continuation) for ADT
• Drug detail: agent, dose, units, wastage for the J-code

• 55715 MUE auto-denial: bill the true lesion count, document each lesion on imaging and in the note, and appeal — do not split lines or under-report [VERIFY: MUE guidance].
• Guidance mismatch: the claim must match the documented guidance modality; fusion codes without documented MRI targeting invite recoupment.
• History-of coded as active (or vice versa): use C61 during treatment/surveillance and Z85.46 after eradication; sequencing errors drive medical-necessity denials on labs and imaging.
• -25 on ADT visits: injection-day E/M requires a significant, separately identifiable service — and payers are scrutinizing modifier -25 closely.
• E/M downcoding: surveillance visits without documented data review and risk discussion are targets for automatic downcoding.

How to choose a biopsy code: first the guidance (ultrasound / MRI-fusion / in-bore), then the approach (transrectal / transperineal), then the targeting (systematic, targeted + systematic, targeted only).

• 55707 – Biopsy, prostate; transrectal, ultrasound guided
• 55709 – transperineal, ultrasound guided
• 55708 – transrectal, ultrasound with MRI fusion, targeted + systematic, first lesion
• 55710 – transperineal, ultrasound with MRI fusion, targeted + systematic, first lesion
• 55711 – transrectal, MRI-ultrasound fusion, targeted only, first lesion
• 55712 – transperineal, MRI-ultrasound fusion, targeted only, first lesion
• 55713 / 55714 – in-bore CT/MRI-guided biopsy, first lesion
• 55715 – each additional lesion (add-on; use with fusion/in-bore codes, not with 55707/55709)
• 55706 – saturation sampling (stereotactic template)

Reminder: descriptor revisions and a new code are proposed for 2027, shifting the family toward lesion-focused fusion language — watch for the final rule [VERIFY: CY2027 proposed changes].

• 76872 – Ultrasound, transrectal
• 84153 – PSA, total; G0103 – PSA screening (Medicare)

• 96402 – Chemotherapy administration, subcutaneous/intramuscular, hormonal anti-neoplastic
• J9217 – Leuprolide acetate (for depot suspension), per 7.5 mg
• J9155 – Degarelix injection
• J9202 – Goserelin acetate implant

• 55866 – Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing (includes robotic assistance)
• 38571 – Laparoscopy, surgical; with bilateral total pelvic lymphadenectomy [VERIFY: NCCI pairing with 55866]

• C61 – Malignant neoplasm of prostate (active disease, including active surveillance and ADT)
• Z85.46 – Personal history of malignant neoplasm of prostate (eradicated, no active treatment)
• Z19.1 / Z19.2 – Hormone sensitive / hormone resistant malignancy status (use additional with C61)
• R97.21 – Rising PSA following treatment for malignant neoplasm of prostate
• R97.20 – Elevated PSA (workup before diagnosis)
• D40.0 – Neoplasm of uncertain behavior of prostate (pathology-confirmed uncertain histology only)

Tip: ICD-10 instructs "use additional code" with C61 for hormone sensitivity status (Z19.1–Z19.2) and rising PSA after treatment (R97.21). For surveillance labs after definitive treatment, sequence the encounter/history codes per payer policy — "history of" codes generally do not belong in the primary position on procedure claims.

• Biopsy targeting: each targeted lesion identified on the previously interpreted MRI and in the procedure note, with matching specimen labels
• Approach and guidance: stated explicitly — they select the code
• Cancer status: active vs history of, risk category, and treatment phase at every visit
• Data reviewed: PSA values and trend, imaging, and pathology referenced in the assessment
• ADT management: drug, dose, schedule, response, side-effect discussion, and continuation decision
• Surgical detail: extent of dissection, nerve sparing, and separately documented lymphadenectomy when performed

• -25 on injection-day E/M only when a significant, separately identifiable service is documented. The CY2027 proposed rule would apply a 50% multiple-service reduction to the lower-valued service on modifier -25 days [VERIFY: proposed rule — not final].
• 51-exempt add-on: no modifier 51 on 55715.

• Biopsy codes (55706–55714): 0-day global; 55715 is an add-on (ZZZ).
• 55866: 90-day global.
• Confirm using your MAC/payer fee schedule.

• 2027 biopsy revisions: proposed CPT® descriptor changes de-emphasize whether fusion was used for regional biopsies and focus fusion on lesion targeting; an additional code and changes to the additional-lesion coding are expected [VERIFY: CY2027 proposed rule].
• In-office biopsy economics: the transperineal codes carry substantially higher office practice expense than transrectal; fusion adds a smaller increment — model volumes and equipment costs before investing.
• Telehealth: surveillance follow-ups qualify for telehealth at parity with in-person payment through 2027 under current policy [VERIFY: policy dates].

• Facility charge capture: same biopsy family as the physician side — 55706–55715 — plus 55866 for robotic radical prostatectomy cases.
• Imaging guidance: 76872 is separately payable in some settings; 76942 is packaged (status indicator N) under OPPS — confirm your setting's packaging [VERIFY: current status indicators].
• ADT drugs: capture J-code units (e.g., J9217, J9155) with wastage documentation; confirm payability by setting — some agents (e.g., J9202) carry restrictive OPPS status [VERIFY: drug status indicators].
• Supplies: biopsy needles, guides, and fusion disposables per facility charge policy and packaging rules.

• C61 – Malignant neoplasm of prostate
• R97.20 – Elevated PSA (pre-diagnosis biopsy encounters)
• Z85.46 – Personal history of malignant neoplasm of prostate
• Z19.1 / Z19.2 – Hormone sensitivity status (with C61)
• R97.21 – Rising PSA following treatment

Facility tip: align dx selection and sequencing with the professional claim; history-of codes in the primary position on procedure claims drive denials.

• Procedure detail: approach, guidance, targeting, and lesion count in the facility record
• Imaging linkage: the MRI report identifying each targeted lesion available for the 55715 appeal file
• Drug documentation: agent, dose, units, wastage on the MAR
• Record alignment: op note, nursing record, pathology requisition/labels, supply log, and charge capture must tell the same story

• Packaging rules vary: imaging guidance and supplies package differently in ASC vs HOPD.
• Site-of-service shifts: biopsy volume is moving toward the office; facilities should track the payment differentials as 2027 practice-expense changes phase in [VERIFY: proposed rule — not final].
• Record review readiness: expect prepayment and post-payment review on multi-unit 55715 claims — assemble the imaging + note appeal file at charge entry.